

CD8 alpha antibody [53-6.7]

Cat. No. GTX00604

Host	Rat
Clonality	Monoclonal
Isotype	IgG2a
Applications	ICC/IF, IHC-P, IHC-Fr, FCM, IP, Depletion
Reactivity	Mouse

References (11)

Package

100 µg

PRODUCT

Summary The 53-6.7 antibody reacts with the 32-34 kDa alpha subunit of mouse CD8, known as CD8a or CD8 alpha. CD8a can form a homodimer (CD8 alpha-alpha), but is more commonly expressed as a heterodimer with a second chain known as CD8b or CD8 beta. CD8 acts as a co-receptor in antigen recognition and subsequent T cell activation that is initiated upon binding of the T cell receptor (TCR) to antigen-bearing MHC Class I molecules. The cytoplasmic domains of CD8 provide binding sites for the tyrosine kinase lck, facilitating intracellular signaling events that lead to T cell activation, development, and cytotoxic effector functions. CD8+ cytotoxic T cells (CTLs) play an important role in inducing cell death of tumor cells, as well as cells infected by virus, bacteria or parasites.

Applications

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.

Suggested dilution	Recommended dilution
ICC/IF	Assay dependent
IHC-P	Assay dependent
IHC-Fr	Assay dependent
FCM	Assay dependent
IP	Assay dependent
Depletion	Assay dependent

Not tested in other applications.

Properties

Form	Liquid
Buffer	10mM NaH ₂ PO ₄ , 150mM NaCl
Preservative	0.09% Sodium azide
Storage	Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4°C.
Concentration	0.5 mg/ml (Please refer to the vial label for the specific concentration.)
Immunogen	Mouse spleen cells



For full product information, images and publications, please visit our [website](#).

Date 2026 / 01 / 11 Page 1 of 2

Purification	Purified by affinity chromatography From tissue culture supernatant
Conjugation	Unconjugated
Note	For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption. Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.



For full product information, images and publications, please visit our [website](#).

Date 2026 / 01 / 11 Page 2 of 2